Pharmaceuticals News and Research

RSS

ACADIA first quarter net loss increases to $6.2 million

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the first quarter ended March 31, 2012.

9 May 2012

Study to analyze effectiveness of weight-loss program on participants with Type 2 diabetes

Diabetes affects nearly 24 million people in the United States, most with Type 2 diabetes, a disease which is often coupled with obesity. Concerned by the increasing number of overweight Americans, nutrition experts with the UC San Diego School of Medicine are launching Take Charge, a research study analyzing the effectiveness of a commercial weight-loss program on participants with Type 2 diabetes who have a BMI of 25 - 45.

9 May 2012

Bayer Yakuhin, Santen enter co-promotion agreement for EYLEA Injection in Japan

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that Bayer's Japanese subsidiary, Bayer Yakuhin, Ltd., and Santen Pharmaceutical Co., Ltd. entered into a co-promotion agreement for EYLEA aflibercept) Injection in Japan.

From Santen Pharmaceutical Co., Ltd. 8 May 2012

Rexahn submits Phase II protocol for Archexin clinical study for ovarian cancer

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase II protocol for the clinical study of Archexin as a treatment of ovarian cancer to the U.S. Food and Drug Administration (FDA).

8 May 2012

First Edition: May 8, 2012

Today's headlines include highlights of how congressional action surrounding the budget and the student loan program could impact health policy.

8 May 2012

FDA approves Clinigen’s Foscavir sNDA to treat HIV/AIDS-related CMV infections and herpes

Clinigen Healthcare, the pharmaceutical products division of Clinigen Group, announced today that its supplemental new drug application (sNDA) for Foscavir (foscarnet sodium), a treatment for HIV/AIDS-related cytomegalovirus (CMV) infections and herpes, has been approved by the US Food and Drug Administration.

From Clinigen Group 8 May 2012

Virginia Premier, Envision announce multi-year PBM agreement

Virginia Premier Health Plan and Envision Pharmaceutical Services, Inc., today announced a multi-year agreement that establishes Envision as the exclusive provider of pharmacy benefit management (PBM) services for Virginia Premier's 150,000 managed Medicaid members starting 7/1/2012. The agreement is based on the pillars of pass-through pricing, transparency and service that will allow Virginia Premier unprecedented plan access and customization while achieving lower net costs.

8 May 2012

Cheaper anti-blindness drug could save NHS £85 million annually

Avastin (bevacizumab), which is used to treat wet age-related macular degeneration – the most common cause of blindness among the elderly costs only £60 per injection. But despite trials showing it is no less effective, another drug, Lucentis, is the current official choice, even though it costs £700 per shot. Avastin is intended to treat bowel cancer, but research by the National Institute for Health Research has shown that it also works just as effectively and safely as Lucentis in treating Wet AMD.

8 May 2012

Abbott to resolve all outstanding issues related to Depakote

Abbott has reached a settlement with U.S. federal and 49 state authorities, plus the District of Columbia, to resolve all outstanding issues regarding a previously disclosed investigation of past sales and marketing practices relating to its neurologic medication Depakote.

8 May 2012

Maxygen first quarter net loss increases to $2.6 million

Maxygen, Inc., a biopharmaceutical company, today announced financial and business results for the quarter ended March 31, 2012.

8 May 2012

Salix first quarter total product revenue increases 62% to $171.1M

Salix Pharmaceuticals, Ltd. today announced financial and operating results for the first quarter ended March 31, 2012 and other business updates.

8 May 2012

T2M cells play a crucial role in treatment-resistant asthma

For most people with asthma, a couple of puffs from an inhaler filled with steroids makes breathing easy. But if their lungs become resistant to the calming effect of that medicine, they live in fear of severe asthma attacks that could send them to the hospital - or worse. Now, new research from the University of Michigan Health System may help explain what's going on in the lungs of these steroid-resistant individuals. The findings could aid the development of new treatment options, and of better ways to identify people at risk of becoming steroid-resistant.

8 May 2012

Otsuka announces results from aripiprazole Phase 3 trial on schizophrenia

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S today announced results from a Phase 3 clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the maintenance treatment of adults with schizophrenia.

8 May 2012

Affymax first quarter total revenue increases to $63.2 million

Affymax, Inc. today reported financial results for the first quarter ended March 31, 2012. The net income for the first quarter of 2012 was $31.5 million (or $0.87 per share) compared to a net loss of $9.6 million (or $(0.36) per share) for the first quarter of 2011.

8 May 2012

Intellect Neurosciences announces two new programs in Alzheimer's disease development pipeline

Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.

7 May 2012

House GOP budget cuts social programs – including Medicaid -- to stave off Pentagon cuts

As Congress returns after a weeklong recess, House Republicans will advance legislation to trim almost $380 billion from the federal budget, with social programs bearing the brunt of the cuts.

7 May 2012

Vertex reports interim data from VX-809 and KALYDECO combination Phase 2 study for cystic fibrosis

Vertex Pharmaceuticals Incorporated announced today an interim analysis of data from an ongoing Phase 2 study of VX-809 and KALYDECO (ivacaftor) that showed significant improvements in lung function (FEV1) among adults with cystic fibrosis (CF) who have two copies.

7 May 2012

Galleon GAL-021 safe and well-tolerated in Phase I respiratory depression clinical study

Galleon Pharmaceuticals, a leader in the development of novel medicines to treat breathing disorders, today announced that its investigational drug GAL-021 appeared to be safe and well-tolerated and demonstrated dose-proportional pharmacokinetic effects on respiration in a Phase I clinical study of 30 healthy adults.

7 May 2012

Nuvo receives BfArM positive opinion for Pliaglis

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced that it has received notice of a positive opinion from the European Decentralized Procedure for the approval of Pliaglis from the German Federal Institute for Drugs and Medical Devices (BfArM), the reference member state.

7 May 2012

Data from Idera IMO-8400 preclinical studies for SLE and psoriasis presented at AAI meeting

Idera Pharmaceuticals, Inc. today announced data from preclinical studies of IMO-8400, demonstrating a novel mechanism of action that may be applicable to the treatment of systemic lupus erythematosus (SLE) and psoriasis. IMO-8400 is an inhibitor of specific Toll-like receptors (TLRs).

7 May 2012